Dermatan sulfate

Dermatan sulfate

Clinical data
AHFS/Drugs.com	International Drug Names
Legal status	?
Identifiers
CAS number	24967-94-0 Y
ATC code	B01AX04
ChemSpider	30361 Y
ChEMBL	CHEMBL1909290 N
Chemical data
Formula	C14H21NO15S2
SMILES [O-]C(=O)[C@@H]2O[C@@H](O[C@H]1[C@@H](OS([O-])(=O)=O)[C@H](O[C@@H](O)[C@@H]1NC(=O)C)CO)[C@H](O)[C@@H](O)[C@@H]2O
InChI InChI=1S/C14H23NO15S/c1-3(17)15-5-10(9(30-31(24,25)26)4(2-16)27-13(5)23)28-14-8(20)6(18)7(19)11(29-14)12(21)22/h4-11,13-14,16,18-20,23H,2H2,1H3,(H,15,17)(H,21,22)(H,24,25,26)/p-2/t4-,5-,6+,7+,8-,9+,10-,11-,13-,14-/m1/s1 Y Key:AVJBPWGFOQAPRH-FWMKGIEWSA-L Y
N (what is this?)  (verify)

Dermatan sulfate is a glycosaminoglycan (formerly called a mucopolysaccharide) found mostly in skin, but also in blood vessels, heart valves, tendons, and lungs.

It is also referred to as chondroitin sulfate B, ^[1] although it is no longer classified as a form of chondroitin sulfate by most sources. The formula is C₁₄H₂₁NO₁₅S.

Function

Dermatan sulfate may have roles in coagulation, cardiovascular disease, carcinogenesis, infection, wound repair, and fibrosis.^[2]

Pathology

Dermatan sulfate accumulates abnormally in several of the mucopolysaccharidosis disorders.

An excess of dermatan sulfate in the mitral valve is characteristic of myxomatous degeneration of the leaflets leading to redundancy of valve tissue and ultimately, mitral valve prolapse (into the left atrium) and insufficiency. This chronic prolapse occurs mainly in women over the age of 60, and can predispose the patient to mitral annular calcification. Mitral valve insufficiency can lead to eccentric (volume dependent or dilated) hypertrophy and eventually left heart failure if untreated.

See also

• iduronic acid

External links

• Dermatan sulfate at the US National Library of Medicine Medical Subject Headings (MeSH)

References